乳腺癌组织中MDR1,TOPOⅡ和C-erbB-2的表达及其相互关系

THE EXPRESSION AND CORRELATION OF MDR1, TOPOⅡ AND C-erbB-2 IN BREAST CANCER

目的 :探索耐药相关基因MDR1和拓扑异构酶TOPOⅡ在乳腺癌中的表达、与肿瘤标志物的关系及其与临床病理特征的关系 ,同时也探讨MDR1和TOPOⅡ与C -erbB - 2共表达的临床意义。方法 :运用免疫组化方法对 94例乳腺癌组织切片MDR1、TOPOⅡ、C -erbB - 2、EGFR、P5 3、PCNA、nm2 3、ER、PR的表达进行检测。结果 :MDR1、TOPOⅡ和C -erbB - 2在乳腺癌中的阳性率分别为 5 2 .1%、4 8.9%和 4 6 .8% ;MDR1和TOPOⅡ均与C -erbB - 2、EGFR、P5 3有相关关系 ,MDR1还和PCNA有关 ;MDR1和TOPOⅡ单独与各项临床病理特征均无关系 ,但TOPOⅡ与C -erbB - 2或MDR1与C -erbB - 2共表达都与肿瘤大小和临床分期有相关关系 ,尤其是TOPOⅡ与C -erbB - 2共表达相关非常显著。结论 :MDR1和TOPOⅡ不仅是肿瘤多药耐药的重要指标 ,它们与C -erbB - 2共表达在对评价乳腺癌肿瘤大小及临床分期上有重要意义。

Objective:To detect the expression of multidrug resistance gene(MDR1) and DNA topoisomerase alphaⅡ(TOPOⅡ) in breast cancer;analyze the relationship between MDR1,TOPOⅡ and several tumor biomarkers, and their relationship with clinical pathological features;further to analyze the co-expression of MDR1, TOPOⅡ with C-erbB-2 and their clinical significance.Methods: MDR1, TOPOⅡ, C-erbB-2, EGFR, P53, PCNA, nm23, ER, PR in 94 patients with breast cancer were determined by immunohistochemistry. Logistic regression and chi-square test were used for analysis.Results:Amplification of MDR1 and TOPOⅡ were 52.1%, 48.9% and 46.8%; MDR1 and TOPOⅡ were both related with C-erbB-2, EGFR and P53,and MDR1 was related with PCNA too; MDR1 and TOPOⅡ were not linked with outcome variables alone. But co-expression of TOPOⅡ with C-erbB-2 or MDR1 with C-erbB-2 correlated with tumor size and clinic stage, especially TOPOⅡ with C-erbB-2 had more significant relation.Conclusions:MDR1 and TOPOⅡ not only play key roles in drug resistance, but also are important in evaluating tumor size and clinic stage when they co-express with C-erbB-2 in breast cancer.